Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gusacitinib (ASN-002) 是一种有效的 SYK 激酶和JAK 激酶的双抑制剂,IC50值为 5 到 46 nM 之间,具有抗癌活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 273 | 现货 | ||
5 mg | ¥ 639 | 现货 | ||
10 mg | ¥ 938 | 现货 | ||
25 mg | ¥ 1,570 | 现货 | ||
50 mg | ¥ 2,880 | 现货 | ||
100 mg | ¥ 5,130 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 993 | 现货 |
产品描述 | Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM). |
靶点活性 | Syk/JAK:5-46 nM |
体外活性 | Gusacitinib (ASN-002) shows anti-proliferative activity in a broad panel of human cancer cell lines including DHL6, DHL4, OCI-LY10, H929, Pfeiffer, HT-1376, and Lovo, suggesting activity in both solid and hematological tumor types[1]. In mechanistic cell-based studies involving IgE and cytokine stimulations, Gusacitinib (ASN-002) strongly suppresses the SYK and JAK family kinase signaling pathways measured as pLAT and pSTAT levels, respectively. |
体内活性 | Gusacitinib (ASN-002) shows a favorable safety profile in rat and dog toxicology studies[1]. Gusacitinib (ASN-002) has good oral bioavailability, metabolic stability, is not a Pgp substrate, and shows little to no inhibition of CYP450 isozymes. In a multiple myeloma (H929) xenograft model, Gusacitinib (ASN-002) exhibits significant efficacy in inhibiting tumor growth (>95%) and it also significantly delays the onset of hind limb paralysis in the human erythroleukemia (HEL) mouse model. |
别名 | ASN-002 |
分子量 | 460.53 |
分子式 | C24H28N8O2 |
CAS No. | 1425381-60-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (206.28 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1714 mL | 10.8571 mL | 21.7141 mL | 54.2853 mL |
5 mM | 0.4343 mL | 2.1714 mL | 4.3428 mL | 10.8571 mL | |
10 mM | 0.2171 mL | 1.0857 mL | 2.1714 mL | 5.4285 mL | |
20 mM | 0.1086 mL | 0.5429 mL | 1.0857 mL | 2.7143 mL | |
50 mM | 0.0434 mL | 0.2171 mL | 0.4343 mL | 1.0857 mL | |
100 mM | 0.0217 mL | 0.1086 mL | 0.2171 mL | 0.5429 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Gusacitinib 1425381-60-7 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors JAK Syk Janus kinase Spleen tyrosine kinase ASN002 ASN 002 Inhibitor inhibit ASN-002 inhibitor